Compare AMCX & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | SGHT |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.6M | 235.0M |
| IPO Year | 2011 | 2021 |
| Metric | AMCX | SGHT |
|---|---|---|
| Price | $9.22 | $4.99 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $7.33 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 398.6K | 314.9K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,311,801,000.00 | $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.41 | $3.11 |
| 52 Week High | $10.28 | $9.24 |
| Indicator | AMCX | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 57.35 |
| Support Level | $6.87 | $4.86 |
| Resistance Level | $10.09 | $5.25 |
| Average True Range (ATR) | 0.45 | 0.40 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 90.18 | 57.24 |
AMC Networks owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.